Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2017

01-01-2017 | Special Article

2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Authors: Fausto Roila, David Warr, Paul J. Hesketh, Richard Gralla, Jorn Herrstedt, Karin Jordan, Matti Aapro, Enzo Ballatori, Bernardo Rapoport

Published in: Supportive Care in Cancer | Issue 1/2017

Login to get access

Abstract

Purpose

An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out.

Methods

A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted.

Results

Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included.

Conclusions

In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.
Literature
1.
Popovic M, Warr DG, Deangelis C, et al. (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22:1685–1697CrossRefPubMed
2.
Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294CrossRefPubMed
3.
Rojas C, Stathis M, Thomas AG, et al. (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478CrossRefPubMed
4.
Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554–1559CrossRef
5.
Inoue A, Yamada Y, Matsumura Y, et al. (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528–532CrossRefPubMed
6.
Hesketh PJ, Bosnjak SM, Nikolic V, et al. (2011) Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer 19:2063–2066CrossRefPubMed
7.
Lindley C, Goodin S, McCune J, et al. (2005) Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 28:270–276CrossRefPubMed
8.
Rapoport B, Jordan K, Boice JA, et al. (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefPubMed
9.
Weinstein C, Jordan K, Green SA, et al. (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172–178CrossRefPubMed
10.
Gralla RJ, Rapoport BL, Jordan K, et al. (2010) Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist aprepitant for all platinum agents: analysis of 1872 patients in prospective randomized clinical phase III trials. J Clin Oncol 28:650s abstract 9057
11.
Jordan K, Gralla R, Rossi G, et al. (2014) Is the addition to an NK1 receptor antagonist beneficial in patients receiving carboplatin? Supplementary data with NEPA, a fixed dose combination of netupitant and palonosetron. Support Care Cancer 22:107s abstract 0162CrossRef
12.
Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. (2016) Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122:2418–2425
13.
Tanioka M, Kitao A, Matsumoto K, et al. (2013) A randomized, placebo controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859–865CrossRefPubMedPubMedCentral
14.
Yahata H, Kobayashi H, Sonoda K, et al (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21(3):491–7. doi:10.​1007/​s10147-015-0928-y
15.
Ito Y, Karayama M, Inui N, et al. (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259–264CrossRefPubMed
16.
Hesketh PJ, Wright O, Rosati G, et al. (2012) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 20:1471–1480CrossRefPubMed
17.
Nishimura J, Satoh T, Fukunaga M, et al. (2015) Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicenter, randomized, controlled phase III trial. Eur J Cancer 51:1274–1282CrossRefPubMed
18.
Molassiotis A, Aapro MA, Dicato M, et al. (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839–848
Metadata
Title
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
Authors
Fausto Roila
David Warr
Paul J. Hesketh
Richard Gralla
Jorn Herrstedt
Karin Jordan
Matti Aapro
Enzo Ballatori
Bernardo Rapoport
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3365-1

Other articles of this Issue 1/2017

Supportive Care in Cancer 1/2017 Go to the issue

Special Article

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Special Article

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Special Article

2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

Special Article

MASCC/ESMO Antiemetic Guidelines: Introduction to the 2016 guideline update

Original Article

Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study

Original Article

Psychological distress of cancer patients with children under 18 years and their partners—a longitudinal study of family relationships using dyadic data analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits